TTIPF (Thiogenesis Therapeutics) FCF Yield %: -20.36 (As of Jun. 24, 2026)


TTIPF Thiogenesis Therapeutics Corp TTIPF
12 GF Score
Price $0.42
! 1 Warning Sign
View Full Analysis

What is Thiogenesis Therapeutics FCF Yield %?

Thiogenesis Therapeutics TTIPF -6.67% 12 FCF Yield % is -20.36 as of Jun. 24, 2026. GuruFocus rates TTIPF with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Thiogenesis Therapeutics ranks worse than 66.76% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Thiogenesis Therapeutics's Trailing 12-Month Free Cash Flow is $-4.29 Mil, and Market Cap is $20.50 Mil. Therefore, Thiogenesis Therapeutics's FCF Yield % for today is -20.36%.

The historical rank and industry rank for Thiogenesis Therapeutics's FCF Yield % or its related term are showing as below:

TTIPF' s FCF Yield % Range Over the Past 10 Years
Min: -20.36   Med: 0   Max: 0
Current: -20.36

TTIPF's FCF Yield % is ranked worse than
66.76% of 1417 companies
in the Biotechnology industry
Industry Median: -9.7 vs TTIPF: -20.36

Thiogenesis Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

Thiogenesis Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Thiogenesis Therapeutics FCF Yield % Related Terms

Thiogenesis Therapeutics FCF Yield % Historical Data

* Premium members only.

The historical data trend for Thiogenesis Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics FCF Yield % Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -14.46

Thiogenesis Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.35 -4,626.73 -20.30 -18.28 -10.38

TTIPF vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Thiogenesis Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thiogenesis Therapeutics FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's FCF Yield % falls into.


TTIPF
12GF Score
Thiogenesis Therapeutics Corp TTIPF
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thiogenesis Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Thiogenesis Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-4.373 / 30.2411224
=-14.46%

Thiogenesis Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.515 * 4 / 19.85474308
=-10.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -20.36 mean?
Thiogenesis Therapeutics (TTIPF) has a FCF Yield % of -20.36 as of Jun. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Thiogenesis Therapeutics and its competitors. According to the industry distribution chart, Thiogenesis Therapeutics ranks #946 out of 1417 companies in the Biotechnology industry, placing it in the top 66.8%.
Is Thiogenesis Therapeutics' FCF Yield % too high?
Thiogenesis Therapeutics' current FCF Yield % is -20.36. Based on the distribution chart, Thiogenesis Therapeutics ranks #946 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Thiogenesis Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Thiogenesis Therapeutics' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thiogenesis Therapeutics ranks #946 out of 1417 companies for FCF Yield %. This places Thiogenesis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Thiogenesis Therapeutics and its competitors. Thiogenesis Therapeutics's current FCF Yield % is -20.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thiogenesis Therapeutics stock overvalued right now?
Thiogenesis Therapeutics (TTIPF) has a current FCF Yield % of -20.36. The current FCF Yield % is -20.36. Thiogenesis Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Thiogenesis Therapeutics (TTIPF), the current FCF Yield % is -20.36 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thiogenesis Therapeutics Business Description

Other Exchanges Q8M:GermanyTTI:Canada
Address 4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotechnology company developing TTI-0102, a novel controlled-release cysteamine prodrug designed to improve tolerability and dosing relative to existing therapies. The Company is focused on TTI-0102 in nephropathic cystinosis, where it is in late-stage development, and is also conducting research and clinical development activities for primary mitochondrial diseases, including Leigh syndrome spectrum disorders.
12GF Score

Get the complete analysis for TTIPF

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price